3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
4
Neoplasms
2
Solid Tumors
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Diseases
1
Genomic Instability
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Interventions
Radiosurgery
23
Temozolomide
14
Magnetic Resonance Spectroscopy
14
pembrolizumab
11
Bevacizumab
11
Nivolumab
10
Ipilimumab
8
Memantine
7
Specimen Handling
6
abemaciclib
5
Radiotherapy
5
Mental Status and Dementia Tests
5
Blood Specimen Collection
5
Radiation
4
entrectinib
3
Surveys and Questionnaires
3
Sodium Chloride
3
Saline Solution
3
Receptors, Interleukin-8B
3
Proton Therapy
3
Lomustine
3
trastuzumab deruxtecan
2
trametinib
2
pertuzumab
2
osimertinib
2
lenvatinib
2
fluciclovine F-18
2
contrast agent BR1
2
atezolizumab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
alectinib
×
90 days
×
Clear all
NCT05987644
2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2
Recruiting
56 enrolled